

Applicant : Henriksson et al.
 Serial No. : 10/525,640
 Filed : February 25, 2005
 Page : 2 of 17


Attorney's Docket No.: 06275-442US1 / 100604-1P US

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof



wherein

X represents ~~an oxygen atom or~~ a group NR^4 ~~or CH_2~~ ;

Y represents NH or N-methyl;

Z^1 and Z^2 each independently represent an oxygen or sulphur atom, provided that at least one of Z^1 and Z^2 represents an oxygen atom;

Either R^1 represents hydrogen or a group selected from C_1 - C_6 alkyl and a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each group being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, carboxyl, $-\text{NR}^5\text{R}^6$, $-\text{CONR}^7\text{R}^8$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylcarbonyl(oxy), $-\text{S}(\text{O})_m\text{C}_1$ - C_6 alkyl where m is 0, 1 or 2, C_1 - C_6 alkylsulphonylamino, C_1 - C_6 alkoxycarbonyl(amino), benzyloxy and a saturated or unsaturated 5- to 6-membered ring which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring in turn being optionally substituted with at least one

Applicant : Henriksson et al
 Serial No. : 10/525,640
 Filed : February 25, 2005
 Page : 3 of 17

Attorney's Docket No.: 06275-442US1 / 100604-1P US

substituent selected from halogen, hydroxyl, oxo, carboxyl, cyano, C₁-C₆ alkyl, C₁-C₆ alkoxy, carbonyl and C₁-C₆ hydroxyalkyl,

R² represents hydrogen or C₁-C₆ alkyl, and

R³ represents hydrogen or C₁-C₆ alkyl,

or

R¹ and R² together with the carbon atoms to which they are attached form a saturated 5- to 6-membered ring optionally comprising a ring heteroatom selected from nitrogen, oxygen and sulphur, and R³ is as defined above,

or

R² and R³ together with the carbon atom to which they are attached form a saturated 5- to 6-membered ring optionally comprising a ring heteroatom selected from nitrogen, oxygen and sulphur, and R¹ is as defined above;

R⁴ represents hydrogen or C₁-C₆ alkyl;

R⁵, R⁶, R⁷ and R⁸ each independently represent hydrogen or C₁-C₆ alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C₁-C₆ alkoxy;

~~L represents CH₂C(O) or C(O)CH₂, or~~


L represents a C₂-C₆ alkyl or C₂-C₆ alkenyl group optionally interrupted or terminated by at least one moiety selected from O, NH, S, SO, SO₂ and C(O), ~~or L represents a C₃-C₆ cycloalkyl, methyl-C₃-C₆ cycloalkyl or C₃-C₆ cycloalkylmethyl group, each of the C₂-C₆ alkyl group recited groups being optionally substituted with at least one substituent selected from hydroxyl, halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy, or~~

~~L represents a C₃-C₄ alkylene chain, the ends of which are attached to adjacent ring carbon atoms in the 5- to 10-membered ring system of G² to form a ring;~~

Applicant : Henriksson et al.
Serial No. : 10/525,640
Filed : February 25, 2005
Page : 4 of 17

Attorney's Docket No.: 06275-442US1 / 100604-1P US

G^2 represents a saturated or unsaturated 5- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, nitro, C_1 - C_6 alkyl (optionally substituted by one or more of cyano, halogen, hydroxyl and methoxy), C_2 - C_6 alkenyl, C_1 - C_6 alkoxy (optionally substituted by one or more halogen atoms), $-S(O)_n C_1$ - C_6 alkyl where n is 0, 1 or 2, C_1 - C_6 alkylcarbonyl(amino), C_1 - C_6 alkylcarbonyloxy, phenyl, benzyloxy, $-NR^9 R^{10}$ and a group of formula



R^9 and R^{10} each independently represent hydrogen or C_1 - C_6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C_1 - C_6 alkoxy;

M represents a bond or $-O-$, $-S-$, $-C\equiv C-$, $-CH_2O-$ or $-OCH_2-$;

G^3 represents an unsaturated 5- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, nitro, C_1 - C_6 alkyl (optionally substituted by one or more of cyano, halogen, hydroxyl and methoxy), C_2 - C_6 alkenyl, C_1 - C_6 alkoxy (optionally substituted by one or more halogen atoms), $-S(O)_t C_1$ - C_6 alkyl where t is 0, 1 or 2, C_1 - C_6 alkylcarbonyl(amino), C_1 - C_6 alkylcarbonyloxy, phenyl, benzyloxy and $-NR^{11} R^{12}$; and

R^{11} and R^{12} each independently represent hydrogen or C_1 - C_6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C_1 - C_6 alkoxy.

Applicant : Henriksson et al.
Serial No. : 10/525,640
Filed : February 25, 2005
Page : 5 of 17

Attorney's Docket No.: 06275-442US1 / 100604-1P US

2. (Cancelled)
3. (Currently Amended) A compound according to claim 2 1, wherein R⁴ represents hydrogen.
4. (Previously Presented) A compound according to claim 1, wherein Y represents NH.
5. (Previously Presented) A compound according to claim 1, wherein Z¹ and Z² both represent an oxygen atom.
6. (Currently Amended) A compound according to claim 1, wherein L represents a C₂-C₄ alkyl group optionally interrupted or terminated by one or two moieties independently selected from O, NH, S, SO, SO₂ and C(O), ~~or L represents a C₃-C₆ cycloalkyl, methylC₃-C₆ cycloalkyl or C₃-C₆ cycloalkylmethyl group, each of the recited groups~~ C₂-C₄ alkyl group being optionally substituted with one or two substituents independently selected from hydroxyl, halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy.
7. (Cancelled)
8. (Cancelled)
9. (Previously Presented) A compound according to claim 1, wherein, in G², the saturated or unsaturated 5- to 10-membered ring system is selected from cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, cyclopentenyl, cyclohexenyl, phenyl, pyrrolidinyl, piperidinyl,

Applicant : Henriksson et al.
Serial No. : 10/525,640
Filed : February 25, 2005
Page : 6 of 17

Attorney's Docket No.: 06275-442US1 / 100604-1P US

piperazinyl, morpholinyl, thiomorpholinyl, diazabicyclo[2.2.1]hept-2-yl, naphthyl, benzofuranyl, benzothienyl, benzodioxolyl, quinolinyl, 2,3-dihydrobenzofuranyl, tetrahydropyranyl, pyrazolyl, pyrazinyl, thiazolidinyl, indanyl, thienyl, isoxazolyl, pyridazinyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, imidazolyl, pyrimidinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl.

10. (Previously Presented) A compound according to claim 1, wherein, in G^3 , the unsaturated 5- to 10-membered ring system is selected from cyclopentenyl, cyclohexenyl, phenyl, naphthyl, benzofuranyl, benzothienyl, benzodioxolyl, quinolinyl, 2,3-dihydrobenzofuranyl, pyrazolyl, pyrazinyl, thiazolidinyl, indanyl, thienyl, isoxazolyl, pyridazinyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, imidazolyl, pyrimidinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl.

11. (Currently Amended) A compound according to claim 1 which is selected from the group consisting of:

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4'-fluoro-biphenyl-4-yl)-ethyl]-acetamide,
N-[2-(4'-Cyano-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
~~2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-phenyl-cyclopropyl)-acetamide,~~
N-[2-(4-Chlorophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
N-(2-Biphenyl-4-yl-ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(7-methyl-1H-indol-3-yl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-phenoxyphenyl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-fluorophenyl)ethyl]-acetamide,
N-[2-(4-Bromophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
N-[2-(2,4-Dichlorophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
N-[2-(3'-Chloro-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
N-[2-(4'-Benzyloxy-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4-thiophen-3-yl-phenyl)ethyl]-acetamide,

Applicant : Henriksson et al.
Serial No. : 10/525,640
Filed : February 25, 2005
Page : 7 of 17

Attorney's Docket No.: 06275-442US1 / 100604-1P US

2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-thiophen-2-yl-phenyl)ethyl]-acetamide,
N-[2-(4'-Chloro-biphenyl-4-yl)-ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4'-methylsulfanyl-biphenyl-4-yl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(3'-nitro-biphenyl-4-yl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4'-methyl-biphenyl-4-yl)ethyl]-acetamide,
N-[2-(3'-Acetylamino-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-naphthalen-2-yl-phenyl)ethyl]-acetamide,
N-[2-(3',5'-Dichloro-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(3'-methyl-biphenyl-4-yl)ethyl]-acetamide,
N-[2-(4-Benzofuran-2-yl-phenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(3'-methoxy-biphenyl-4-yl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-[1,1';4',1'']terphenyl-4-ylethyl]-acetamide,
N-[2-(4'-Acetyl-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
N-[2-(4-Benzo[b]thiophen-2-yl-phenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
N-[2-(4'-Cyanomethyl-biphenyl-4-yl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-pyridin-3-yl-phenyl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-[4-(1H-pyrrol-2-yl)phenyl]ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-furan-3-yl-phenyl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-furan-2-yl-phenyl)ethyl]-acetamide,
2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-thiophen-2-yl-ethyl)-acetamide,
N-[2-(4-tert-Butylphenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,
N-[2-(4-Chlorophenyl)-1-methylethyl]-2-(2,5-dioxoimidazolidin-4-yl)acetamide,
~~N-[[1-(4-Chlorophenyl)cyclopropyl]methyl]-2-(2,5-dioxoimidazolidin-4-yl)acetamide,~~
~~N-2,3-Dihydro-1H-inden-2-yl-2-(2,5-dioxoimidazolidin-4-yl)acetamide,~~
N-[2-(4-Chlorophenyl)ethyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetamide,
N-[2-(4-Chlorophenyl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetamide,
N-[2-(4'-Cyano-1,1'-biphenyl-4-yl)ethyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetamide,

Applicant : Henriksson et al.
Serial No. : 10/525,640
Filed : February 25, 2005
Page : 8 of 17

Attorney's Docket No.: 06275-442US1 / 100604-1P US

N-[2-(4'-Fluoro-1,1'-biphenyl-4-yl)ethyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(4'-fluoro-1,1'-biphenyl-4-yl)propyl]-acetamide,

~~*N* [(1*S*,2*R*) 2-(4'-Methoxybiphenyl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~*N* [(1*S*,2*R*) 2-(4'-Cyanobiphenyl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~*N* [(1*S*,2*R*) 2-(4'-Acetylbiphenyl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~*N* [(1*S*,2*R*) 2-(4'-(Acetylamino)biphenyl-4-yl)cyclopropyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

N-[2-(4'-Cyanobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(3'-methoxybiphenyl-4-yl)ethyl]-acetamide,

N-[2-(4'-Cyano-3'-methylbiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-methyl-*N*-(2-phenylethyl)-acetamide,

N-[1-(4-Chlorophenyl)ethyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-hydroxy-1-methyl-2-phenylethyl)-acetamide,

N-{2-[4-(1,3-Benzodioxol-5-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-[2-(3'-methoxybiphenyl-4-yl)propyl]-acetamide,

N-{2-[3'-(Acetylamino)biphenyl-4-yl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[2-(3'-Acetylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[2-(4'-Acetylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-{2-[4-(1-Benzothien-2-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[2-(3'-Cyanobiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[2-(4'-Cyanobiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

Applicant : Henriksson et al.
Serial No. : 10/525,640
Filed : February 25, 2005
Page : 9 of 17

Attorney's Docket No.: 06275-442US1 / 100604-1P US

2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4'-fluoro-3'-methylbiphenyl-4-yl)propyl]-
acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-N-{2-[3'-(methylthio)biphenyl-4-yl]propyl}-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-N-{2-[4-(6-methoxypyridin-3-yl)phenyl]propyl}-
acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4'-methoxy-3'-methylbiphenyl-4-yl)propyl]-
acetamide,

N-{2-[4-(2,3-Dihydro-1-benzofuran-5-yl)phenyl]propyl}-2-(2,5-dioxoimidazolidin-4-yl)-
acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-N-{2-[3'-(trifluoromethoxy)biphenyl-4-yl]propyl}-
acetamide,

N-[2-(3',4'-Dimethoxybiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-N-[2-(4-quinolin-3-ylphenyl)propyl]-acetamide,

N-[2-(4'-Cyano-3'-methylbiphenyl-4-yl)propyl]-2-(2,5-dioxoimidazolidin-4-yl)-
acetamide,

~~N-[5-(1,3-Benzodioxol-5-yl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-
acetamide,~~

~~2-(2,5-Dioxoimidazolidin-4-yl)-N-[5-(3-methoxyphenyl)-2,3-dihydro-1H-inden-2-yl]-
acetamide,~~

~~N-[5-[3-(Acetylamino)phenyl]-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-
yl)-acetamide,~~

~~N-[5-(3-Acetylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-
acetamide,~~

~~N-[5-(4-Acetylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-
acetamide,~~

~~N-[5-(1-Benzothien-2-yl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-
acetamide,~~

Applicant : Henriksson et al.
Serial No. : 10/525,640
Filed : February 25, 2005
Page : 10 of 17

Attorney's Docket No.: 06275-442US1 / 100604-1P US

~~N-[5-(3-Cyanophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[5-(4-Cyanophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~2-(2,5-Dioxoimidazolidin-4-yl)-N-[5-(4-fluoro-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-acetamide,~~

~~2-(2,5-Dioxoimidazolidin-4-yl)-N-[5-[3-(methylthio)phenyl]-2,3-dihydro-1H-inden-2-yl]-acetamide,~~

~~2-(2,5-Dioxoimidazolidin-4-yl)-N-[5-(6-methoxypyridin-3-yl)-2,3-dihydro-1H-inden-2-yl]-acetamide,~~

~~2-(2,5-Dioxoimidazolidin-4-yl)-N-[5-(4-methoxy-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-acetamide,~~

~~N-[5-(2,3-Dihydro-1-benzofuran-5-yl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)acetamide,~~

~~N-[5-(3,4-Dimethoxyphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[2-(4'-Fluorobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[2-[4-(1,3-Benzodioxol-5-yl)phenyl]propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[2-(3'-Methoxybiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[2-[4-(1-Benzothien-2-yl)phenyl]propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[2-(3'-Cyanobiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[2-(4'-Fluoro-3'-methylbiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

Applicant : Henriksson et al.
Serial No. : 10/525,640
Filed : February 25, 2005
Page : 11 of 17

Attorney's Docket No.: 06275-442US1 / 100604-1P US

2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-N-{2-[3'-(methylthio)biphenyl-4-yl]propyl}-acetamide,

N-{2-[4-(6-Methoxypyridin-3-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

N-[2-(4'-Methoxy-3'-methylbiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

N-{2-[4-(2,3-Dihydro-1-benzofuran-5-yl)phenyl]propyl}-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-N-{2-[3'-(trifluoromethoxy)biphenyl-4-yl]propyl}-acetamide,

N-[2-(3',4'-Dimethoxybiphenyl-4-yl)propyl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-N-[2-(4-quinolin-3-ylphenyl)propyl]-acetamide,
~~N-[5-(4-Fluorophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[5-(1,3-Benzodioxol-5-yl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[5-(3-Methoxyphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[5-[3-(Acetylamino)phenyl]-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[5-(3-Acetylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[5-(4-Acetylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[5-(1-Benzothien-2-yl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

Applicant : Henriksson et al.
Serial No. : 10/525,640
Filed : February 25, 2003
Page : 12 of 17

Attorney's Docket No.: 06275-442US1 / 100604-1P US

~~N-[5-(3-Cyanophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[5-(4-Cyanophenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[5-(4-Fluoro-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-N-[5-[3-(methylthio)phenyl]-2,3-dihydro-1H-inden-2-yl]-acetamide,~~

~~N-[5-(6-Methoxypyridin-3-yl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[5-(4-Methoxy-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[5-(2,3-Dihydro-1-benzofuran-5-yl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~2-(4-Methyl-2,5-dioxoimidazolidin-4-yl)-N-[5-[3-(trifluoromethoxy)phenyl]-2,3-dihydro-1H-inden-2-yl]-acetamide,~~

~~N-[5-(3,4-Dimethoxyphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-[5-(4-Cyano-3-methylphenyl)-2,3-dihydro-1H-inden-2-yl]-2-(4-methyl-2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-{4-[4-(trifluoromethyl)phenoxy]phenyl}ethyl)-acetamide,~~

~~2-(2,5-Dioxoimidazolidin-4-yl)-N-{2-[4-(4-methoxyphenoxy)phenyl]ethyl}-acetamide,~~

~~2-(2,5-Dioxoimidazolidin-4-yl)-N-(2-{4-[4-(trifluoromethoxy)phenoxy]phenyl}ethyl)-acetamide,~~

~~N-(2-[4-(4-Chlorophenoxy)phenyl]ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~N-(2-[4-(4-Acetylphenoxy)phenyl]ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,~~

~~2-(2,5-Dioxoimidazolidin-4-yl)-N-{2-[4-(pyridin-3-yloxy)phenyl]ethyl}-acetamide,~~

Applicant : Henriksson et al.
 Serial No. : 10/525,640
 Filed : February 25, 2005
 Page : 13 of 17

Attorney's Docket No.: 06275-442US1 / 100604-1P US

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-{4-[(6-methoxypyridin-3-yl)oxy]phenyl}ethyl)-acetamide,

N-(2-[4-(4-Cyanophenoxy)phenyl]ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-[4-(4-methylphenoxy)phenyl]ethyl)-acetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-[4-(4-fluorophenoxy)phenyl]ethyl)-acetamide,

N-(2-Biphenyl-4-yl-2-hydroxy-ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-(2-(1,1'-Biphenyl-4-yl)-2-methoxyethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

N-(2-(1,1'-Biphenyl-4-yl)-ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-*N*-methylacetamide,

2-(2,5-Dioxoimidazolidin-4-yl)-*N*-(2-(4-phenylethynyl)-piperidin-1-yl)ethyl]-acetamide,


N-(2-[(4-Bromobenzyl)oxy]ethyl)-2-(2,5-dioxoimidazolidin-4-yl)-acetamide,

~~2-(1,1'-Biphenyl-4-yl)-2-oxoethyl-2-(2,5-dioxoimidazolidin-4-yl)acetate,~~


and pharmaceutically acceptable salts and solvates thereof.

12. (Currently Amended) A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in claim 1 which comprises,

(a) ~~when X represents an oxygen atom or a group NR⁴~~, reacting a compound of formula



wherein X¹ represents an ~~oxygen atom or~~ a group NR⁴ and L, G² and R⁴ are as defined in claim 1, formula (I), with an activated carboxylic acid of formula




wherein Y, Z¹, Z², R¹, R² and R³ are as defined in claim 1, formula (I); ~~or~~


Applicant : Henriksson et al.
 Serial No. : 10/325,640
 Filed : February 25, 2005
 Page : 14 of 17

Attorney's Docket No.: 06275-442US1 / 100604-1P US


~~(b) when X represents CH_2 , reacting an activated carboxylic acid of formula (IV) as defined in (a) above with methoxymethylamine or a salt thereof followed by reaction with a Grignard reagent of formula~~



~~wherein Hal represents a halogen atom and L and G^2 are as defined in claim 1, formula (I); or~~
~~(e) when X represents CH_2 , reacting a compound of formula~~



~~wherein Y, Z^1 , Z^2 , R^1 , R^2 and R^3 are as defined in claim 1, formula (I), with a compound of formula~~



~~wherein LG^1 represents a leaving group and L and G^2 are as defined in claim 1, formula (I) in the presence of a strong base;~~

~~and optionally after (a), (b) or (e) forming a pharmaceutically acceptable salt or solvate.~~

13. (Previously Presented) A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier.

14. (Previously Presented) A process for the preparation of a pharmaceutical composition which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or

Applicant : Henriksson et al.
Serial No. : 10/525,640
Filed : February 25, 2005
Page : 15 of 17

Attorney's Docket No.: 06275-442US1 / 100604-1P US

solvate thereof as defined in claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

15-19. (Cancelled)

20. (Currently Amended) A method of treating ~~The method of claim 19, wherein the obstructive airways disease is asthma or chronic obstructive pulmonary disease~~ which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1.

21. (New) A method of treating chronic obstructive pulmonary disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1.

22. (New) A method of treating arthritis which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1.

23. (New) The method of claim 22, wherein the arthritis is rheumatoid arthritis or osteoarthritis.

24. (New) A method of treating atherosclerosis which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1.

25. (New) A method of treating restenosis which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1.